je.st
news
European Commission Approves Mercks Anti-PD-1 Therapy, KEYTRUDA (pembrolizumab), for Both First-line and Previously-treated Patients with Advanced Melanoma
2015-07-22 13:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KEYTRUDA Demonstrated Superior Survival versus Ipilimumab in a Phase 3 Clinical Trial KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the treatment of advanced (unresectable or metastatic) melanoma in adults. The European Commission approval of KEYTRUDA is based on data from three clinical studies conducted in more than 1,500 first-line and previously-treated patients with advanced melanoma. Language: English Contact: MerckMedia:Pamela Eisele, (267) 305-3558orAn Phan, (908) 255-6325orInvestor:Joseph Romanelli, (908) 740-1986orJustin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
advanced
european
commission
Category:Biotechnology and Pharmaceuticals